Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

Mar 11 2011

• By The Pink Sheet Daily

Related Content

GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010

Feb 03 2011

Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab

Oct 18 2007

GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes

Oct 23 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window